felzartamab - Search News

BIIB Starts Felzartamab Phase III Study in AMR

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Markets Insider · 4d

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a

Nasdaq · 3d

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Pharmabiz · 2d

Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST]

Biogen announces initiation of dosing in TRANSCEND

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Nasdaq4d

Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

Felzartamab is still an investigational drug that has not yet received regulatory approval, which poses a risk for investors and stakeholders regarding its eventual market success. The need for a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

BIIB Starts Felzartamab Phase III Study in AMR

Trending now